Literature DB >> 17258444

Changes in sputum composition during 15 min of sputum induction in healthy subjects and patients with asthma and chronic obstructive pulmonary disease.

Olga Toungoussova1, Giovanni B Migliori, Maria P Foschino Barbaro, Luisa M Esposito, Silvano Dragonieri, Giovanna E Carpagnano, Francesco G Salerno, Margherita Neri, Antonio Spanevello.   

Abstract

INTRODUCTION: The use of sputum induction by inhalation of hypertonic saline to study the cellular and biochemical composition of the airways allows noninvasive sampling of the airways content and identification of markers of airways inflammation.
OBJECTIVE: The present study aimed to identify possible changes in the cellular composition of induced sputum between samples obtained sequentially (three periods of 5 min each) during one sputum induction. Moreover, difference between these samples and the mixed one (mixture of samples obtained after 5, 10 and 15 min of induction) was investigated.
METHODS: Forty-six subjects (10 healthy volunteers, 12 patients with chronic obstructive pulmonary disease (COPD) and 24 patients with asthma) (mean age 53.0+/-14.0 yr, forced expiratory volume in one second (FEV(1)) 71.8+/-19.0% pred) produced sputum after three consecutive 5 min periods of hypertonic (4.5%) saline inhalation. Stained cytospins from the three periods separately and from the mixed sample were produced and analyzed.
RESULTS: The mean percentage of neutrophils, eosinophils, lymphocytes and epithelial cells did not change significantly in samples obtained consecutively after 5, 10 and 15 min of the induction procedure. There was no significant difference in the cellular composition of samples obtained after 5, 10 and 15 min of induction and the cellular composition of the mixed sample (P=0.06).
CONCLUSION: The separate analysis of induced sputum from three consecutive sampling and the mixed sample did not demonstrate significant changes in their cellular composition. Fifteen minutes induction procedure with the fixed concentration of hypertonic saline and processing of the mixed sample can be recommended for clinical settings and clinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258444     DOI: 10.1016/j.rmed.2006.12.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

Review 1.  Hypertonic Solution in Severe COVID-19 Patient: A Potential Adjuvant Therapy.

Authors:  Matheus Gennari-Felipe; Leandro Borges; Alexandre Dermargos; Eleine Weimann; Rui Curi; Tania Cristina Pithon-Curi; Elaine Hatanaka
Journal:  Front Med (Lausanne)       Date:  2022-06-21

2.  Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury.

Authors:  Neal S Gould; Steve Gauthier; Chirag T Kariya; Elysia Min; Jie Huang; Day J Brian
Journal:  Respir Res       Date:  2010-08-27

Review 3.  Hypertonic saline in treatment of pulmonary disease in cystic fibrosis.

Authors:  Emer P Reeves; Kevin Molloy; Kerstin Pohl; Noel G McElvaney
Journal:  ScientificWorldJournal       Date:  2012-05-03

4.  Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controls.

Authors:  Nobuhisa Ishikawa; Noboru Hattori; Nobuoki Kohno; Akihiro Kobayashi; Tomoyuki Hayamizu; Malcolm Johnson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-01-23

5.  Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab.

Authors:  Giovanna E Carpagnano; Giulia Scioscia; Donato Lacedonia; Giacomo Curradi; Maria Pia Foschino Barbaro
Journal:  J Asthma Allergy       Date:  2019-03-05

6.  The Role of Airways 17β-Estradiol as a Biomarker of Severity in Postmenopausal Asthma: A Pilot Study.

Authors:  Giulia Scioscia; Giovanna Elisiana Carpagnano; Donato Lacedonia; Piera Soccio; Carla Maria Irene Quarato; Luigia Trabace; Paolo Fuso; Maria Pia Foschino Barbaro
Journal:  J Clin Med       Date:  2020-06-29       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.